A wealth of GPCR ligand binding site data is available from structures and mutants.

Integrating structural and mutant data is a tool to design mutagenesis experiments.

Ligand molecular interactions are better discriminated by multiple residue mutants.

New functional and mechanistic insights are keys towards tailored drug actions.